Clinical and microbiological characteristics of neonates with bacteremia by NDM-producing Klebsiella pneumoniae in a peruvian referral hospital
DOI:
https://doi.org/10.17843/rpmesp.2026.432.15600Keywords:
Newborn, Bacteremia, Klebsiella pneumoniae, Carbapenem-Resistant Enterobacteriaceae, PeruAbstract
We conducted a descriptive cross-sectional study in the neonatology service of the Hospital Nacional Guillermo Almenara Irigoyen (2020-2024) to characterize the clinical and microbiological profile of neonates with carbapenemase-producing Klebsiella pneumoniae bacteremia. Nineteen neonates were included; most were preterm and low birth weight, and approximately half presented bacteremia secondary to a respiratory focus. All strains carried the blaNDM gene. In vitro, 84.2% (16/19) were susceptible to amikacin and 40% (6/15) to tigecycline. All isolates had intermediate susceptibility to colistin and resistance to multiple antimicrobials. Empirical therapy was appropriate in 7/16 (43.8%) and about a fifth of the patients died. The identification of blaNDM reinforces the importance of local genomic surveillance to guide empirical therapy. The type of carbapenemase and its impact on mortality is a future research gap.
Downloads
References
Zhou R, Fang X, Zhang J, Zheng X, Shangguan S, Chen S, et al. Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis. BMJ Open. 2021;11(12):e054971. doi: 10.1136/bmjopen-2021-054971.
Thomas R, Ondongo-Ezhet C, Motsoaledi N, Sharland M, Clements M, Velaphi S. Incidence and All-Cause Mortality Rates in Neonates Infected With Carbapenem Resistant Organisms. Front Trop Dis [Internet]. 2022 [citado el 27 de agosto de 2025];3. doi: 10.3389/fitd.2022.832011.
Villegas MV, Jiménez A, Esparza G, Appel TM. Carbapenemase-producing Enterobacteriaceae: A diagnostic, epidemiological and therapeutic challenge. Infectio. 2019;388–97. doi: 10.22354/in.v23i4.808.
WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance [Internet]. [citado el 27 de agosto de 2025]. Disponible en: https://www.who.int/publications-detail-redirect/9789240093461
Ding Y, Wang Y, Hsia Y, Sharland M, Heath PT. Systematic review of carbapenem-resistant Enterobacteriaceae causing neonatal sepsis in China. Ann Clin Microbiol Antimicrob. 2019;18(1):36. doi: 10.1186/s12941-019-0334-9.
Hu Y, Yang Y, Feng Y, Fang Q, Wang C, Zhao F, et al. Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries. PLoS Med. 2023;20(6):e1004233. doi: 10.1371/journal.pmed.1004233.
Almeida TL, Mendo T, Costa R, Novais C, Marçal M, Martins F, et al. Carbapenemase-Producing Enterobacteriaceae (CPE) Newborn Colonization in a Portuguese Neonatal Intensive Care Unit (NICU): Epidemiology and Infection Prevention and Control Measures. Infect Dis Rep. 2021;13(2):411–7. doi: 10.3390/idr13020039.
Escobar Pérez JA, Olarte Escobar NM, Castro-Cardozo B, Valderrama Márquez IA, Garzón Aguilar MI, Martinez de la Barrera L, et al. Outbreak of NDM-1-producing Klebsiella pneumoniae in a neonatal unit in Colombia. Antimicrob Agents Chemother. 2013;57(4):1957–60. doi: 10.1128/AAC.01447-12.
Barroso M do V, da Silva CR, Benfatti LR, Gozi KS, de Andrade LK, Andrade LN, et al. Characterization of KPC-2-producing Klebsiella pneumoniae and affected patients of a pediatric hospital in Brazil. Diagn Microbiol Infect Dis. 2023;106(2):115932. doi: 10.1016/j.diagmicrobio.2023.115932.
Falco A, Ramos Y, Franco E, Guzmán A, Takiff H. A cluster of KPC-2 and VIM-2-producing Klebsiella pneumoniae ST833 isolates from the pediatric service of a Venezuelan Hospital. BMC Infect Dis. 2016;16(1):595. doi: 10.1186/s12879-016-1927-y.
Krapp F, García C, Hinostroza N, Astocondor L, Rondon CR, Ingelbeen B, et al. Prevalence of Antimicrobial Resistance in Gram-Negative Bacteria Bloodstream Infections in Peru and Associated Outcomes: VIRAPERU Study. Am J Trop Med Hyg. 2023;109(5):1095–106. doi: 10.4269/ajtmh.22-0556.
Lee C-C, Lee C-H, Yang C-Y, Hsieh C-C, Tang H-J, Ko W-C. Beneficial effects of early empirical administration of appropriate antimicrobials on survival and defervescence in adults with community-onset bacteremia. Crit Care. 2019;23:363. doi: 10.1186/s13054-019-2632-1.
Spivak ES, Cosgrove SE, Srinivasan A. Measuring Appropriate Antimicrobial Use: Attempts at Opening the Black Box. Clin Infect Dis. 2016;63(12):1639–44. doi: 10.1093/cid/ciw658.
M100 | Performance Standards for Antimicrobial Susceptibility Testing [Internet]. [citado el 27 de agosto de 2025]. Disponible en: https://clsi.org/shop/standards/m100/
Ara-Montojo MF, Escosa-García L, Alguacil-Guillén M, Seara N, Zozaya C, Plaza D, et al. Predictors of mortality and clinical characteristics among carbapenem-resistant or carbapenemase-producing Enterobacteriaceae bloodstream infections in Spanish children. J Antimicrob Chemother. 2021;76(1):220–5. doi: 10.1093/jac/dkaa397.
Meng H, Yang J, Niu M, Zhu H, Zhou Y, Lu J. Risk factors and clinical outcomes of carbapenem-resistant Klebsiella pneumoniae bacteraemia in children: a retrospective study. Int J Antimicrob Agents. 2023;62(4):106933. doi: 10.1016/j.ijantimicag.2023.106933.
Gadisa E, Egyir B, Fekede E, Adu B, Danso J, Oclu A, et al. Epidemiology, antimicrobial resistance profile, associated risk factors and management of carbapenem resistant Klebsiella pneumoniae in children under 5 with suspected sepsis in Ethiopia. BMC Infect Dis. 2024;24:1458. doi: 10.1186/s12879-024-10366-4.
Chiotos K, Hayes M, Gerber JS, Tamma PD. Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. J Pediatric Infect Dis Soc. 2020;9(1):56–66. doi: 10.1093/jpids/piz085.
Fang P, Gao K, Yang J, Li T, Sun Q, Shan Z, et al. Clinical characteristics and risk factors for neonatal bloodstream infection due to carbapenem-resistant Enterobacteriaceae: A single-centre Chinese retrospective study. J Glob Antimicrob Resist. 2024;37:28–36. doi: 10.1016/j.jgar.2024.02.004.
Nour I, Eldegla HE, Nasef N, Shouman B, Abdel-Hady H, Shabaan AE. Risk factors and clinical outcomes for carbapenem-resistant Gram-negative late-onset sepsis in a neonatal intensive care unit. J Hosp Infect. 2017;97(1):52–8. doi: 10.1016/j.jhin.2017.05.025.
Ruvinsky S, Voto C, Roel M, Portillo V, Naranjo Zuñiga G, Ulloa-Gutierrez R, et al. Carbapenem-Resistant Enterobacteriaceae Bacteremia in Pediatric Patients in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. Antibiotics (Basel). 2024;13(12):1117. doi: 10.3390/antibiotics13121117.
Marino A, Pulvirenti S, Campanella E, Stracquadanio S, Ceccarelli M, Micali C, et al. Ceftazidime-Avibactam Treatment for Klebsiella pneumoniae Bacteremia in Preterm Infants in NICU: A Clinical Experience. Antibiotics (Basel). 2023;12(7):1169. doi: 10.3390/antibiotics12071169.
IETSI - EsSalud. Eficacia y seguridad de ceftazidima-avibactam en pacientes pediatricos de 3 meses a más con sepsis causada por bacterias Gram-negativas productoras de carbapenemasas y resistentes a colistina. Dictamen Preliminar de Evaluación de Tecnología Sanitaria N.° 022-DETS-IETSI-2023. Lima, Perú. 2023.
Bradley J, Roilides E, Tawadrous M, Yan JL, Soto E, Stone GG, et al. Pharmacokinetics and Safety of Ceftazidime-Avibactam in Neonates and Young Infants: A Phase 2a, Multicenter Prospective Trial. J Pediatric Infect Dis Soc. 2025;14(5):piaf028. doi: 10.1093/jpids/piaf028.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Flavia Lara-Herrera, Ana Amable-Castilla, Daniela Mori-Rodriguez, Giancarlo Pérez-Lazo
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
